Full notification file
General informationNotification NumberB/FR/15/GT03Member State to which the notification was sentFranceDate of acknowledgement from the Member State Competent Authority31/12/2014Title of the ProjectThe clinical study to be conducted with JX-594 is entitled:
“A phase Ib/II study of metronomic cyclophosphamide and the oncolytic poxvirus JX-594 in
patients with advanced breast cancer and advanced soft tissue sarcoma”. The clinical study
short title is METROmaJX.Proposed period of release:01/11/2014 to 01/11/2017Name of the Institute(s) or Company(ies)Institut Bergonié, Centre Régional de Lutte contre le Cancer de Bordeaux
et du Sud-Ouest
229 cours de l’Argonne
33076 Bordeaux Cedex
France;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:DNA VirusIdentity of the GMO:Genus: Orthopoxvirus
Species: Vaccinia virus (VV)Information relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | - | orthopoxvirus | vaccinia virus | - | Wyeth | - |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known